



## DAFTAR PUSTAKA

- Abbas, M., Jadidi, F., 2012. The deviated balance between regulatory T cell and Th17 in autoimmunity. *J. Immunopharm-Immunot.* 34(5):727-739
- Abbas, H., Geirsson, A., Singh, M., Ali, R., Juan, A., 2012. Modulation of transforming growth factor signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. *Circulation.* [126\(11\):189-197](#)
- Bayat, A., McGrouther, D.A., Ferguson, M.W.J., 2003. Skin scarring. *Br. Med. J.* 326:88-92.
- Beer, T.W., 2005. Keloid are not angiogenic lesions. *J. Am. Acad. Dermatol.* 53:1097-1098
- Bettinger, D. A., Yager, D.R., Diegelmann, R.F., Cohen, I.K., 1996. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. *J. Plast. Reconstr. Surg.* 98:827-833
- Bran, G.M., Goessler, U.R., Bafitri, A., Horman, K., Riedel, F., Sadick, H., 2010. Effect of transforming growth factor-beta1 antisense oligonucleotide on matrix metalloproteinases and their inhibitors in keloid fibroblasts. *J. Otolaryngol-Head. Neck. Surg.* 143(1):66-71
- Broughton, G., Janis, J.E., Attinger, C.E., 2006. Wound healing: An overview. *J. Plast. Reconstr. Surg.* 117:1-32
- Burrows, N.P. & Lovell, C.R., 2004. Keloid and hypertrophic scars. *Rook's Textbook of Dermatology.* 7thEd. USA; Blackwell Publishing:54-56
- Butler, P.D., Longkaker, M.T., Yang, G.P., 2008. Current progress in keloid research and treatment. *J. Am. Coll. Surg.* 206:731-741.
- Caulfield, R.H., Tyler, M.P., Austyn, J.M., Dziewulski, P., McGrouther, D.A., 2008. The Relationship between protease/antiprotease profile, angiogenesis and re-epithelisation in acute burn wounds. *J. Plast. Reconstr. Surg.* 134:474-486
- Chau, C.H., Clavijo, C.A., Deng, H.T., 2005. Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. *Am. J. Physiol. Cell.* 289:444-454
- Chike-Obi, C. J., Cole, P. D., Brisset, A. E., 2009. Keloids: pathogenesis, clinical features and management. *Seminar in Plastic Surgery,* 23(3):178-184
- Crowther, J.R., 2001. The ELISA guidebook. *Humana Press,* New Jersey:407



Dachlan, I., 2015. Pengembangan 5 $\alpha$ -oleandrin isolasi dari daun kembang mentega (*Nerium indicum* Mill) sebagai obat anti keloid: kajian *in vitro* pada sel fibroblas keloid [Disertasi]. Yogyakarta: Univ. Gadjah Mada

Darby, I.A., Laverdet, B., Bonte, F., Desmouliere, A., 2014. Fibroblasts and myofibroblasts in wound healing. *Dovepress*. 7:301-311

Dey, P. & Chaudhuri, T. K., 2014. Pharmacological aspect of *Nerium Indicum* Mill: a comprehensive review. *Pharmacog. Rev.* 8(16):156-162

Duffy, A.M., Bouchier-Hayes, D.J., Harmey, J.H., 2000. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. *Madame Curie Bioscience Database*

Edriss, A.S., 2005. Management of keloid and hypertrophic scars. *Ann. Burns and Fire Disasters*. 18(4):202-210

Fearnley, G.W., Smith, G.A., Harrison, M.A., Wheatcroft, S.B., Tomlison, D.C., Ponnabalam, S., 2013. Vascular endothelial growth factors regulation of blood vessels sprouting in health and disease. *OA Biochemistry*. 1(1):5-14

Felippe, C., Ribeiro, A., Ignatio, C., 2017. Review: Na/K pump and beyond: NA/K-ATPase as a modulator of apoptosis and autophagy. *Molecules*. 22:578-582

Fujiwara, M., Muragaki, Y., Ooshima, A., 2005. Keloid-derived fibroblast show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. *Br. J. Dermatol.* 153(2):295-300

Gabhann, F.M., Qutub, A.A., Annex, B.H., Popel, A.S., 2010. Systems biology of pro-angiogenic therapies targeting the VEGF System : *Wiley Interdiscip Rev.Syst. Biol.Med.* 2(6):694-707

Gilbert, R.W.D., Vickaryous, M.K., Vilorio-Petit, A.M., 2016. Signalling by transforming growth factor beta isoforms in wound healing and tissue regeneration. *J. Dev. Biol.* 4:21-23

Gurtner, G.C., Werner, S., Barrandon, Y., Longaker, M.T., 2008. Wound repair and regeneration. *Nature*. 453:314–321

Gira, A.K., Brown, L.F., Washington, C.V., Cohen, C., and Arbiser, J.L., 2004. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. *J. Am. Acad. Dermatol.* 50:850–853

Halim, A.S., Emami, A., Salahshourifar, I., Kannan, T.P., 2012. Keloid scarring: understanding the genetic basis, advances and prospects. *Arch. Plast. Surg.* 39: 184-189



Hicklin, D.J., 2004. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J. Clin. Oncol.* 23:1011-1027

Iozzo, R.V., 1997. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. *J. Crit. Rev. Biochem. Mol. Biol.* 32(2):141-174

Jagadeesan, J.& Bayat, A., 2007. Transforming growth factor beta (TGF $\beta$ ) and keloid disease. *Int. J. Surg.* 5:278-285

Karamysheva, A.F., 2008. Mechanism of angiogenesis. *J. Biochem. Mosc.* 73:751-762

Lee, S.S., Yosipovitch, G., Chan, Y.H., Goh, C.L., 2004. Pruritus, pain, and small nerve fiber function in keloids: A controlled study. *J. Am. Acad. Dermatol.* 51:1002-1006

Lee, C.H., Hong, C.H., Chen, Y.T., Chen, Y.C., Shen, M.R., 2012. TGF-Beta increases cell rigidity by enhancing expression of smooth muscle actin keloid-derived fibroblasts as a model for cellular mechanisms. *J. Dermatol. Sci.* 67(3):173-180

Lorquet, S., Berndt, S., Blacher, S., Gengoux, E., Peulen, O., Maquoi, E., 2010. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. *FASEB J.* 24:3782-3795

Louw, L., 2007. The keloid phenomenon: progress toward a solution. *J. Clin. Anat.* 20:3-14

Maneros, A.G., Krieg, T., 2004. Keloid-clinical, pathogenesis, and treatment options. *J. Dtsch. Dermatol. Ges.* 2:905-913

Manna, K. S., Sah, K. N., Newman, A. R., Cisneros, A., Aggarl, B. B., 2000. Oleandrin supresses activation of nuclear transcription factor- $\kappa$ B, activator protein-1 and C-Jun NH<sub>2</sub> terminal kinase. *J. Cancer Res.* 60:3838-3847

Mccarty, S.M., Syed, F., Ayat, A., 2010. Influence of the human leukocyte antigen complex on the development of cutaneous fibrosis: an immunogenetic perspective. *J. Acta. Derm. Venereol.* 90: 563-574

Meerlo, J.V., Kaspers, G.J.L.& Cloos, J., 2011. Cell sensitivity assay: The MTT assay in cancer cell culture. *Humana Press:* 237-245

Miller, M.C., Nanchahal, J., 2005. Advances in the modulation of cutaneous wound healing and scarring. *Biodrug.* 19(6):363-381



Mustoe, T.A, Cooter, R.D., Gold, M.H, Hobbs, R., Ramelet, A.A., Shakespeare, P.G., 2002. International clinical recommendations on scar management. *J. Plast. Reconstr. Surg.* 110:560-571

Nagase, H., Visse, R., Murphy, G., 2006. Structure and function of matrix metalloproteinases and TIMPs. *J. Cardiovasc. Res.* 69(3):562-73

O’Kane, S., 2002. Wound remodelling and scarring. *J.Wound Care.* 11:296-299

Ollson, A. K., Dimberg, A., Kruger, J., Welsh, L. 2006. VEGF-A receptor signalling in control of vascular function. *J. Mol. Cell. Biol.* 7:359-369

Peakman, M., Vergani, D., 2009. Basic and Clinical Immunology, Second Edition, *Churchill Livingstone Elsevier*: London

Penn, J.W., Adriaan O.G., Kerstin, J.R., 2012. The role of the TGF- $\beta$  family in wound healing, burns and Scarring: a review article. *Int. J. Burn. Trauma.* 2(1):18-28

Perdanakusuma, D.S. dan Noer, M.S., 2006. Penanganan parut hipertrofik dan keloid. *Airlangga University Press*: Surabaya

Rao, K., Malathi, N., Narashiman, Rahan, T., 2014. Evaluation of myofibroblast by expression of alpha smooth muscle actin: a marker in fibrosis, dysplasia and carcinoma. *J. Clin. Diag. Res.* 8(4):12-15

Reuben, P.M., Cheung, H.S., 2006. Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. *J. Front. Biosci.* 11:1199-215

Robles, D.T., Berg, D., 2007, Abnormal wound healing: keloids. *J. Clin. Dermatol.* 25:26-32

Sadick, H., Herberger, A., Riedel, K., Bran, G., Goessler, U., Hoermann, K., Riedel, F., 2008. TGF- beta 1 antisense therapy modulates expression of matrix metalloproteinases in keloid derived fibroblasts. *Int. J. Mol. Med.* 22:55-60

Saito, T., Takeda, N., Amiya, E., Nakao, T., Abe, H., Semba, H., 2013. VEGF-A induces its negative regulator, soluble form of VEGFR-1 by modulating its alternative splicing. *FEBS Lett.* DOI: S0014-5793(13)00392

Seifert, O., Mrowietz, U., 2009. Keloid Scarring : Bench and Bedside. *J. Arch. Dermatol. Res.* 301:259-272

Seo, B.F., Lee, J.Y., and Jung, S.N., 2013. Models of abnormal scarring. *BioMed Res. Int.* Article ID 423147:1-8



Shah, M., Foreman, D.M., Ferguson, M.W., 1995. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. *J. Cell. Sci.* 108(3):985-1002

Shejbal, D., Bedeković, V., Lvkić, M., Kalogjera, L., Aleric, Z., Draviš, P., 2004. Strategies in the treatment of keloid and hypertrophic scarr. *Acta. clin. Croat.* 43:417-422

Shi, C.M., Cheng, T.M., Su, Y.P., 2004. Effect of dermal multipotent cell transplantation on skin wound healing. *J. Surg. Res.* 121(1):13-19

Shih, B., Garside, E., McGrouther, D.A., Bayat, A., 2010. Molecular dissection of abnormal wound healing processes resulting in keloid disease. *J. Wound. Rep. Reg.* 18:139–153

Sinto, L., 2018. Skar hipertropik dan keloid: patofisiologi dan penatalaksanaan. *Cermin Dunia Kedokteran.* Jakarta. 260 (45):29-32

Slemp, A.E., Kirsner, R.E., 2006. "Keloid and scars : a review of keloid and scars, their pathogenesis, risk factors, and management". *J. Curr. Opin. Pediatr.* 18(4): 396-402

Smith, J.C., Boone, B.E., Opalenik, S.R., Williams, S.M., Russel, S.B., 2008. Gene profiling of keloid fibroblastts shows altered expression in multiple fibrosis-associated pathways. *J. Invest. Dermatol.* 128:1298-1310

Tang, M., Bian, W., Cheng, L., Zhang, L. 2018. Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF- $\beta$ /Smad and ERK signaling pathways. *Int. J. Mol. Med.* 41:1487-1499

Viera, M.H., Vivas, A.C., Berman, B., 2013. Update on keloid management: Clinical and basic science advances. *J. Adv. Wound care (New Rochelle).* 1(5):200-206

Vijayvergia, R. & Kumar, J., 2007. Quantification of primary metabolites of *Nerium Indicum* Mill. *Asian J. Exp. Biol. Sci.* 21(1):123-128

Wahyuningsih, M.S.H., Wahyuono, S., 1999. Skrining toksisitas dengan BST dari daun beberapa spesies tanaman yang secara tradisional untuk mengobati tumor di Indonesia. *BIK.* 31(1):17-22. *Lab Invest.* 88(6):579–590

Wahyuningsih, M.S.H., Mubarika, S., 2004. Sitotoksitas oleandrin hasil isolasi dari daun *Nerium indicum* Mill terhadap beberapa kultur sel kanker manusia. *Majalah Farmasi Indonesia.* 15(2):47-54



Wahyuningsih, M.S.H., Mubarika, S., Hamman, T.M., 2008. Identifikasi struktur senyawa berpotensi anti-kanker ginjal yang selektif dari daun *Nerium indicum* Mill. *Majalah Farmasi Indonesia*. 19(2):57-64

Wahyuningsih, M.S.H., Yuliani, F.S., Rahmawati, D.Y., Nurul, A., 2018. Efek antifibrotik ekstrak etanol *Nerium indicum* Mill dengan marker  $5\alpha$ -oleandrin pada sel fibroblas keloid. *J. Tradit. Complement Med*. 23(1):70-78

Wahyuningsih, M.S.H., Agungnugraha, D.A., Budiyanto, A., 2019. Ethanolic extract of *Tithonia diversifolia* (Hemsley) A. Gray inhibits migration activity and decrease the transforming growth factor-Beta1, VEGF expression on keloid fibroblasts. *Asian J. Pharm. Clin. Res*. 12(1):342-345

Wall, S.J., Bevan, D., Thomas, D.W., Harding, K.G., Edwards, D.R., Murphy, G., 2002. Differential expression of matrix metalloproteinases during impaired wound healing of the diabetic mouse. *J. Invest. Dermatol*. 119:91-98

Wang, J., Zohar, R., McCulloch, C.A., 2006. Multiple roles of  $\alpha$ -smooth muscle actin in mechanotransduction. *J. Exp. Cell. Res*. 312(3):205–214

Wang, X.Q., Lu, S.L., Mao, Z.G., Liu, Y.K., 2007. Study on the biological function of vascular endothelial cells in the hypertrophic scar. Article in Chinese: *Zhonghua Shao Shang Za Zhi*. 23(3):219-221

Wilgus, T.A., Ferreira, A.M., Oberyszyn, T.M., Bergda, V.K., DiPietro, L.A., 2012. Regulation of scar formation by vascular endothelial growth factor. *J. Invest. Dermatol*. 132(2):493–494

Wolff, K., *et al.*, 2008. *Fitzpatrick's Dermatology in General Medicine*. 7th ed. New York: Mc Graw-Hill

Wolfram, D., Tzankov, A., Pulzl, P., Piza-Katzer, H. 2009. Hypertrophic scars and keloids: a review of their pathophysiology, risk factors and therapeutic management. *J. Dermatol. Surg*. 35:171

Wu, W.S., Wang, F.S., Yang, K.D., Haung, C.C., Dacks, J.M., 2006. Dexamethasone induction regresion through effective suppression of VEGF expression and keloid fibroblast proliferation. *J. Invest. Dermatol*. 126:1264-1271